how long have glp-1 drugs been on the market Trends and Global Forecasts Report 2025: A $157.5 Bn Market by 2035 Market Overview: GLP-1 Agonists and

Aging Is No Longer Just a Matter of Time Every cell in the body constantly manages damage, repairs molecular structures, and maintains the systems required for life

Therapies that offer better efficacy could be saved for sicker diabetic patients

Patients face these permanent life-altering consequences from NAION-related blindness: Sudden blindness in affected eye: Most experience dense altitudinal visual field loss affecting top or bottom half, with some suffering complete blindness Inability to drive or work: Vision loss severe enough to disqualify from driving and render many occupations impossible Constant risk to fellow eye: Living with approximately 15% risk over five years that the second eye will suffer identical fate No restorative treatment options: Unlike cataracts, NAION leaves patients with zero medical solutions for recovery Permanent disability from NAION has made these injuries central to litigation

Glucagon-like peptide-1 receptor agonist use and the risk of residual gastric contents and aspiration in patients undergoing GI endoscopy: a systematic review and meta-analysis

GLP-1 receptor agonists attach to GLP-1 receptors on pancreatic -cells, triggering adenylate cyclase activation and elevating cAMP levels inside the cells

Weight loss represents a significant secondary goal alongside diabetes management for many who select this option